Medical Condition

hematologic malignancy

Total Trials

11

Recruiting Now

11

Trial Phases

Phase 1, Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for hematologic malignancy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hematologic malignancy Clinical Trials

How many clinical trials are currently recruiting for hematologic malignancy?

ClinicalMetric currently tracks 11 actively recruiting clinical trials for hematologic malignancy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 11. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for hematologic malignancy?

hematologic malignancy research spans Phase 1 (3 trials), Phase 2 (2 trials), Phase 3 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a hematologic malignancy clinical trial?

Eligibility criteria for hematologic malignancy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Phase 4

Top Sponsors

St. Jude Children's Research Hospital 1 trial

Novartis Pharmaceuticals 1 trial

Hangzhou Weben Pharma Co., Ltd 1 trial

Thomas Jefferson University 1 trial

University Hospital Tuebingen 1 trial

Recruiting Clinical Trials

NCT07257419 Phase 1

Recruiting

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

St. Jude Children's Research H...

View Trial →

NCT06401356 Phase 3

Recruiting

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Enrollment

50 pts

Location

United States, Belgi...

Sponsor

Novartis Pharmaceuticals

View Trial →

NCT07014449 Phase 1

Recruiting

Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

Hangzhou Weben Pharma Co., Ltd

View Trial →

NCT07121140

Recruiting

Home Blood Transfusions

Thomas Jefferson University

View Trial →

NCT05943067 Phase 1, Phase 2

Recruiting

CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT

University Hospital Tuebingen

View Trial →

NCT07133074 Phase 4

Recruiting

Allergy Delabeling in Antibiotic Stewardship - Intervention

Abramson Cancer Center at Penn...

View Trial →

NCT07035938

Recruiting

T-cell Developmental Status in Patients With Malignant Hematological Tumors

The First Affiliated Hospital ...

View Trial →

NCT05417971

Recruiting

Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation

Northside Hospital, Inc.

View Trial →

NCT05529069 Phase 2

Recruiting

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

M.D. Anderson Cancer Center

View Trial →

NCT06532773

Recruiting

Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

National Cancer Institute (NCI...

View Trial →

Related Conditions

relapsed pediatric all (1) hematopoietic cell transplantation (1) solid tumor (1) advanced malignancies (1) aml acute myelogenous leukemia (1) relapsed acute myelogenous leukemia (1) refractory acute myeloid leukemia (1) c myc (1) adult acute myeloid leukemia (1) myelodysplastic syndromes (1) acute myeloid leukemia (1) transfusion dependent cytopenias (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology